Combination inhibitor strategies targeting KRAS effector signaling in KRAS-mutant pancreatic cancer.

被引：0
|
作者：
Ozkan-Dagliyan, Irem [1 ]
Goodwin, Craig M. [1 ]
Bryant, Kirsten L. [1 ]
George, Samuel D. [1 ]
Lucas, Kelly [1 ]
Gautam, Prson [2 ]
Wennerberg, Krister [2 ]
Cox, Adrienne D. [1 ]
Der, Channing J. [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC 27515 USA
[2] Inst Mol Med Finland, Helsinki, Finland
来源：
MOLECULAR CANCER RESEARCH | 2020年 / 18卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B31
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [41] Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
    Linehan, Anna
    O'Reilly, Mary
    McDermott, Ray
    O'Kane, Grainne M.
    FRONTIERS IN MEDICINE, 2024, 11
  • [42] Dissecting tumor cell heterogeneity to identify therapeutic vulnerabilities in Kras-mutant lung cancer.
    Padhye, Aparna
    Rodriguez, B. Leticia
    Fradette, Jared J.
    Ungewiss, Christin
    Gibbons, Don L.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 55 - 55
  • [43] KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
    Karimi, Nastaran
    Moghaddam, Seyed Javad
    CELLS, 2023, 12 (05)
  • [44] Mutant KRAS in the initiation of pancreatic cancer
    Deramaudt, T
    Rustgi, AK
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2005, 1756 (02): : 97 - 101
  • [45] Targeting metabolic peculiarities: a potentially novel therapeutic approach for KRAS-mutant lung cancer?
    Abdel-Rahman, Omar
    JOURNAL OF THORACIC DISEASE, 2016, 8 (08) : E794 - E795
  • [46] Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities
    Zhang, Jun
    Park, Dongkyoo
    Shin, Dong M.
    Deng, Xingming
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2016, 48 (01) : 11 - 16
  • [47] Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.
    Arbour, Kathryn Cecilia
    Ricciuti, Biagio
    Rizvi, Hira
    Hellmann, Matthew D.
    Yu, Helena Alexandra
    Ladanyi, Marc
    Kris, Mark G.
    Arcila, Maria E.
    Rudin, Charles M.
    Lito, Piro
    Awad, Mark M.
    Riely, Gregory J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
    Liu, Weiran
    Yin, Yuesong
    Wang, Jun
    Shi, Bowen
    Zhang, Lianmin
    Qian, Dong
    Li, Chenguang
    Zhang, Hua
    Wang, Shengguang
    Zhu, Jinfang
    Gao, Liuwei
    Zhang, Qiang
    Jia, Bin
    Hao, Ligang
    Wang, Changli
    Zhang, Bin
    ONCOTARGET, 2017, 8 (01) : 179 - 190
  • [49] Expanded access program of the PLK1 inhibitor onvansertib for treatment of patients with KRAS-mutant metastatic colorectal cancer.
    Sharma, Manish R.
    Isaac, Daniel
    Ramaekers, Ryan
    Ridinger, Maya
    Erlander, Mark
    Mendelsohn, Lawrence
    CANCER RESEARCH, 2021, 81 (13)
  • [50] Chromatin condensation in KRAS-mutant lung cancer as a therapeutic target: challenging the paradigm of associating KRAS mutation with EGFR inhibitor resistance
    Wang, Meng
    Kern, Ashley M.
    Huelskoetter, Marieke
    Greninger, Patricia
    Singh, Anurag
    Pan, Yunfeng
    Chowdhury, Dipanjan
    Krause, Mechthild
    Baumann, Michael
    Benes, Cyril H.
    Efstathiou, Jason A.
    Settleman, Jeff
    Willers, Henning
    CANCER RESEARCH, 2014, 74 (19)
12345